Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Activmed Practices and Research

Neither a doctor nor a teaching hospital

Research payments

$1,277,446

23 payments

Through program year 2025, Activmed Practices and Research is reported as receiving $1,277,446 in research payments, across 23 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $574 3
2024 Research $16,944 2
2023 Research $30,246 2
2022 Research $34,050 2
2021 Research $383,190 4
2020 Research $340,691 6
2019 Research $471,752 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $1,193,119 11 payments
  2. Novartis Pharmaceuticals Corporation $70,982 10 payments
  3. Amgen Inc. $13,289 1 payment
  4. Pfizer Inc. $56 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $487,472 4 payments
  2. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $403,174 3 payments
  3. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $180,872 2 payments
  4. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $121,601 2 payments
  5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $68,121 6 payments
  6. US Pt Satisfaction $13,289 1 payment
  7. Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $2,500 1 payment
  8. A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS) $348 1 payment
  9. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $56 1 payment
  10. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of Lnp023 in Primary Iga Nephropathy Patients $13 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record